TrialThe Lancet. Oncology2013

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).

Ruth E Langley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.